A study to identify the potential effects of extracorporeal shockwave therapy alone and in combination with Avastin. - Breast cancer is characterized by rapid aberrant growth of tissue in the mammary glands. The speed of cancer growth is enabled by the rapid development of a robust vasculature to provide nutrients to the tumors. One relatively recent approach to mitigating cancer growth is to inhibit the development of the vasculature supplying blood to the tumor. One drug that has shown substantial success in this is bevacizumab (Avastin, Genentech). Avastin targets a growth factor that signals for vascular development. By interfering with this signaling pathway this drug slows the growth of tumors, and has been shown to enhance the therapeutic effects of other chemotherapy drugs. The FDA has approved Avastin in combination with Paclitaxel (Bristol-Myers Squibb) for the treatment of breast cancer.

Shock wave therapy alone has no impact on cancer growth - Cancer remains one of the leading causes of morbidity and mortality throughout the world. Several types of cancer do not respond to first line therapies, such as chemotherapy and radiotherapy, and one of the major challenges is to find effective anticancer treatments able to completely eradicate the tumor, while keeping systemic toxicity at minimum . In recent decades, various tumor-targeted therapeutic approaches have been developed at a molecular, cellular and tissue level

Selective sensitiveness of mesenchymal stem cells to shock waves leads to anticancer effect in human cancer cell co-cultures - Mesenchymal stem cells (MSC) possess the distinctive feature of homing in on and engrafting into the tumor stroma making their therapeutic applications in cancer treatment very promising. Research into new effectors and external stimuli, which can selectively trigger the release of cytotoxic species from MSC toward the cancer cells, significantly raises their potential.

Clinical Outcomes of Extracorporeal Shock Wave Therapy in Patients With Secondary Lymphedema: A Pilot Study - In a prospective clinical trial, ESWT was performed consecutively 4 times over two weeks in 7 patients who were diagnosed with stage 3 secondary lymphedema after breast cancer treatment. Each patient was treated with four sessions of ESWT (0.056—0.068 mJ/mm2 , 2,000 impulses).